Burton L Eisenberg
Affiliation: Dartmouth Medical School
- The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumorsBurton L Eisenberg
Department of Surgery, Section of Surgical Oncology, Geisel School of Medicine at Dartmouth Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
Am J Clin Oncol 36:89-90. 2013..1 year of adjuvant IM has established a benefit of RFS and OS for the 3 year cohort. Future studies are necessary to continue to further delineate risk variables for GIST recurrence...
- Gastrointestinal stromal tumor--background, pathology, treatmentBurton L Eisenberg
Surgical Oncology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
Hematol Oncol Clin North Am 26:1239-59. 2012..The success of molecular targeted therapy in GIST represents an important and exciting advance in solid tumor oncology...
- Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trialsBurton L Eisenberg
Department of Surgery, Surgical Oncology, Darthmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA
Clin Colorectal Cancer 6:S24-9. 2006..The results of these studies will be meaningful in future standard therapy consideration...
- Adjuvant and neoadjuvant therapy for primary GISTBurton L Eisenberg
Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Section of Surgical Oncology, Lebanon, NH, USA
Cancer Chemother Pharmacol 67:S3-8. 2011..Advantages can include tumor downsizing to provide opportunity for less morbid surgical resection as well as to decrease risk of intra-op tumor rupture. These theoretical considerations have not been evaluated in large clinical studies...
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665Burton L Eisenberg
Section of Surgical Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
J Surg Oncol 99:42-7. 2009..There have been no prospective studies either evaluating the neoadjuvant use of IM in primary GIST or as a preoperative cytoreduction agent for metastatic GIST...
- Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapyBurton L Eisenberg
Section of Surgical Oncology, Norris Cotton Cancer Center, Rubin Building, 8th Floor, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
Ann Surg Oncol 11:465-75. 2004..g., rendering initially inoperable tumors resectable) in the overall management approach to advanced GIST may contribute to surgeons' success in attaining this objective...
- A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissueMargit M McGowan
Section of Hematology Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, and Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
Breast Cancer Res Treat 138:175-83. 2013..CLA consumption was well-tolerated and safe at this dose for up to 20 days. Overall, CLA may be a prototype compound to target fatty acid synthesis in breast cancers with a "lipogenic phenotype"...
- Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumorsBurton L Eisenberg
Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH, USA
Int J Cancer 129:2533-42. 2011..This article reviews pivotal efficacy and safety data for adjuvant imatinib and explores the potential clinical benefit of neoadjuvant imatinib in patients with GIST...
- Lipoprotein lipase links dietary fat to solid tumor cell proliferationNancy B Kuemmerle
Section of Hematology and Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
Mol Cancer Ther 10:427-36. 2011..Interfering with dietary fat intake, lipolysis, and/or FA uptake will be necessary to target the requirement of cancer cells for FA...
- Fatty acid synthesis is a therapeutic target in human liposarcomaArne M Olsen
Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
Int J Oncol 36:1309-14. 2010..These findings warrant further studies aimed at the clinical exploitation of the dependence of LS cell growth on fatty acids...
- Is reporting of recurrence data important in pancreatic cancer?Michael O Meyers
Department of Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Ann Surg Oncol 11:304-9. 2004..The purpose of this study was to identify patients with recurrent pancreatic cancer and to determine whether treatment after recurrence had any effect on outcome...
- Combined-modality strategy for gastrointestinal stromal tumorsBurton L Eisenberg
Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH 03756, USA
Semin Oncol 33:S75-8. 2006..The continued study of combining surgery and a target-specific agent for malignant GIST will be a valuable reference for future strategies combining surgery and targeted treatment in other solid tumors...
- Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cellsChristina Donnelly
Department of Medicine, Section of Endocrinology and Metabolism, and the Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
Nutr Cancer 61:114-22. 2009..Rescue from the antiproliferative effect of CLA by palmitic acid indicates that reduced tumor lipogenesis is a major mechanism for the anticancer effects of CLA...
- The association of cytokeratin-only-positive sentinel lymph nodes and subsequent metastases in breast cancerPhilip S Mullenix
Department of Surgery, Madigan Army Medical Center, 9040A Reid Street, Tacoma, WA 98431, USA
Am J Surg 189:606-9; discussion 609. 2005..The purpose of this study was to better characterize the clinical significance of cytokeratin immunohistochemistry (IHC)-only-positive lymph node metastases among patients with breast cancer...
- Pharmacotherapy of gastrointestinal stromal tumoursBurton L Eisenberg
Department of Surgical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Expert Opin Pharmacother 4:869-74. 2003..These initial evaluations with imatinib mesylate provide proof of concept for hypothesis driven, rational drug design of selective signal transduction inhibitors in the management of solid tumour malignancies...
- Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumorsBurton L Eisenberg
Department of Surgical Oncology, Fox Chase Cancer Center, Temple University, School of Medicine, Philadelphia, Pennsylvania, USA
Oncology (Williston Park) 17:1615-20; discussion 1620, 1623, 1626 passim. 2003..The initial evaluations of imatinib provide proof of concept for the hypothesis-driven design of selective molecularly targeted therapies for solid tumor malignancies...
- En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?Aaron R Sasson
Department of Surgical Oncology, Temple University School of Medicine, Philadelphia, PA 19111, USA
J Gastrointest Surg 6:147-57; discussion 157-8. 2002....
- Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich
Division of Hematology Oncology, Department of Pathology, Oregon Health and Science University Cancer Institute, Oregon Health and Science University, Portland, OR, USA
J Clin Oncol 24:4764-74. 2006..In clinical studies, 75% to 90% of patients with advanced GISTs experience clinical benefit from imatinib. However, imatinib resistance is an increasing clinical problem...
- Intraoperative radiotherapy in the multimodality approach to bone and soft tissue cancersRodney J Ellis
Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106 6068, USA
Surg Oncol Clin N Am 12:1015-29. 2003..As IORT use becomes more common, special care will be required to ensure that it is used by a multidisciplinary team of radiation oncologists and surgeons to ensure the best results for patients...
- Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyRobert F Ozols
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 25:146-62. 2007..This report demonstrates the essential role of clinical cancer research in finding new and better ways to treat, diagnose, and prevent a group of diseases that strike half of men and one-third of women in the United States...
- Soft tissue sarcomas of adults: state of the translational scienceErnest C Borden
The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA
Clin Cancer Res 9:1941-56. 2003..Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality...
- Epidemiology of GISTCharles Blanke
Am J Gastroenterol 100:2366. 2005
- Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcomeAaron R Sasson
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Gastrointest Cancer 34:121-8. 2003..Although retrospective,this series suggests an improvement in survival in patients treated with neoadjuvant therapy...